Linagliptin (Trajenta®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy

• in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; as combination therapy
• in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;
• in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and
• in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.